Next Article in Journal
A Brief Overview of lncRNAs in Endothelial Dysfunction-Associated Diseases: From Discovery to Characterization
Next Article in Special Issue
An Epigenetics-Based Hypothesis of Autoantigen Development in Systemic Lupus Erythematosus
Previous Article in Journal
Behavioral Epigenetics: Perspectives Based on Experience-Dependent Epigenetic Inheritance
Previous Article in Special Issue
Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren’s Syndrome and Primary Biliary Cholangitis
Review

Targeting HDAC Complexes in Asthma and COPD

Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, 9713 AV Groningen, The Netherlands
*
Author to whom correspondence should be addressed.
Epigenomes 2019, 3(3), 19; https://doi.org/10.3390/epigenomes3030019
Received: 28 June 2019 / Revised: 2 September 2019 / Accepted: 4 September 2019 / Published: 7 September 2019
(This article belongs to the Special Issue Complex Disease Epigenetics)
Around three million patients die due to airway inflammatory diseases each year. The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD). Therefore, new therapies are urgently needed. Promising targets are histone deacetylases (HDACs), since they regulate posttranslational protein acetylation. Over a thousand proteins are reversibly acetylated, and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD. The diverse set of selective and non-selective HDAC inhibitors used in pre-clinical models of airway inflammation show promising results, but several challenges still need to be overcome. One such challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards specific HDAC complexes. Novel strategies to disrupt HDAC complexes should be developed to validate HDACs further as targets for new anti-inflammatory pulmonary treatments. View Full-Text
Keywords: asthma; COPD; inflammation; NF-κB; HDAC; acetylation; post translational modification (PTM); inhibitor; drug design; co-repressor complex; review asthma; COPD; inflammation; NF-κB; HDAC; acetylation; post translational modification (PTM); inhibitor; drug design; co-repressor complex; review
Show Figures

Graphical abstract

MDPI and ACS Style

Zwinderman, M.R.H.; de Weerd, S.; Dekker, F.J. Targeting HDAC Complexes in Asthma and COPD. Epigenomes 2019, 3, 19. https://doi.org/10.3390/epigenomes3030019

AMA Style

Zwinderman MRH, de Weerd S, Dekker FJ. Targeting HDAC Complexes in Asthma and COPD. Epigenomes. 2019; 3(3):19. https://doi.org/10.3390/epigenomes3030019

Chicago/Turabian Style

Zwinderman, Martijn R.H., Sander de Weerd, and Frank J. Dekker. 2019. "Targeting HDAC Complexes in Asthma and COPD" Epigenomes 3, no. 3: 19. https://doi.org/10.3390/epigenomes3030019

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop